



an Open Access Journal by MDPI

Bacterial Pathogenesis and Antimicrobial Strategy

Guest Editors:

Dr. Juan C. Vázquez-Ucha

Servicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain

Dr. Marta Martínez-Guitián

Servicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain

Deadline for manuscript submissions: closed (30 April 2023)



mdpi.com/si/103617

Message from the Guest Editors

Antibiotic resistance a major global health problem. The emergence of infections caused by multidrug-resistant (MDR) pathogens is becoming increasingly common, including the identification of strains resistant to all or almost all available drugs. Moreover, bacteria also produce a variety of virulence factors that enhance colonisation of the host and the development of infection, such as the presence of pilus or flagella, capsule formation, toxins production, or biofilm development, among others. Many of these virulence factors are also transmissible between pathogens.

This Special Issue aims to provide new insights into bacterial pathogenesis and antimicrobial resistance in both Gram-positive and Gram-negative bacteria. In particular, we will focus on (i) the identification and description of new resistance mechanisms and/or virulence factors, (ii) the activity of new antimicrobials or antivirulence compounds, (iii) the relationship between virulence and antimicrobial resistance, and (iv) the identification and description of new therapeutic targets. Research papers, communications, short notes, and reviews related to these topics are welcome for this Special Issue.







an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supragovernmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/antibiotics antibiotics@mdpi.com X@antibioticsmdpi